Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Jul;7(4):441-6.
doi: 10.2174/157016209788680552.

Impact of prior HAART use on clinical outcomes in a large Kenyan HIV treatment program

Michael H Chung  1 , Alison L Drake, Barbra A Richardson, Ashok Reddy, Joan Thiga, Samah R Sakr, James N Kiarie, Paul Yowakim, Grace C John-Stewart
Affiliations

Impact of prior HAART use on clinical outcomes in a large Kenyan HIV treatment program

Michael H Chung et al. Curr HIV Res. 2009 Jul.

Abstract

Background: HIV treatment programs in Africa typically approach all enrolling patients uniformly. Growing numbers of patients are antiretroviral experienced. Defining patients on the basis of antiretroviral experience may inform enrollment practices, particularly if medical outcomes differ.

Methods: Baseline and follow-up measures (CD4, weight change, and survival) were compared in a retrospective analysis between antiretroviral-naïve (ARV-N) and antiretroviral experience (ARV-E) patients enrolled at the Coptic Hope Center for Infectious Diseases in Nairobi, Kenya and followed between January 2004 and August 2006.

Results: 1,307 ARV-N and 962 ARV-E patients receiving highly active antiretroviral therapy (HAART) were followed for median of 9 months (interquartile range: 4-16 months). Compared to ARV-N, ARV-E had substantially higher CD4 count (median cells/mm(3), 193 versus 95, P < 0.001) and weight (median kg, 62 versus 57, P < 0.001) at baseline, and lower rates of change in CD4 (-9.2 cells/mm(3)/month; 95% CI, -11.4 -7.0) and weight (-0.24 kg/month; 95% CI, -0.35 - -0.14) over 12 months. Mortality was significantly higher in ARV-N than ARV-E (P = 0.001).

Conclusions: ARV-E patients form a growing group that differs significantly from ARV-N patients and requires a distinct approach from ARV-N clients. Systematic approaches to streamline care of ARV-E patients may allow focused attention on early ARV-N clients whose mortality risks are substantially higher.

PubMed Disclaimer

Figures

Fig. (1)
Fig. (1)
Flowchart of adult patients enrolling at the Coptic Hope Center for Infectious Diseases between January 2004 and August 2006.
Fig. (2)
Fig. (2)
Scatterplot of CD4 count over time by antiretroviral exposure at baseline. Curves represent locally weighted smoothed curves of CD4 count over time, by ARV status. Time = Time since enrollment
Fig. (3)
Fig. (3)
Scatterplot of weight over time by antiretroviral exposure at baseline. Curves represent locally weighted smoothed curves of weight over time, by ARV status. Time = time since enrollment
Fig. (4)
Fig. (4)
Kaplan-Meier plot of survival by antiretroviral exposure at baseline. Time = time since enrollment
See this image and copyright information in PMC

References

    1. Katabira ET, Oelrichs RB. Scaling up antiretroviral treatment in resource-limited settings: successes and challenges. AIDS. 2007;21(Suppl 4):S5–10. - PubMed
    1. Fairall LR, Bachmann MO, Louwagie GM, et al. Effectiveness of antiretroviral treatment in a South African program: a cohort study. Arch Intern Med. 2008;168:86–93. - PubMed
    1. Severe P, Leger P, Charles M, et al. Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med. 2005;353:2325–34. - PubMed
    1. Stringer JS, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA. 2006;296:782–93. - PubMed
    1. Wools-Kaloustian K, Kimaiyo S, Diero L, et al. Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya. AIDS. 2006;20:41–8. - PubMed

Publication types

Substances